Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE
China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its...
August 2023
Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions
The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment...
Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials
China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...
Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer
Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...
FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer
The US Food and Drug Administration (FDA) has granted priority review status to the submission...
Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns
Scott-Moncrieff & Associates, a UK-based law firm, has disclosed that it is preparing nearly 50...
Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China
Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received...
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Johnson & Johnson Completes Spinoff of Kenvue as Independent Company
Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its...
Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress
China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first...
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Study
China-based Lynk Pharmaceuticals Co., Ltd has announced positive topline results from the Phase II clinical...
Allist Pharmaceuticals’ Furmonertinib Wins NMPA Nod for EGFR-Mutated NSCLC Treatment
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced that it has received clinical approval from...
Zai Lab’s Repotrectinib Targets Breakthrough Therapy Designation for TRK-Positive Tumors
The Center for Drug Evaluation (CDE) website has indicated that repotrectinib, a next-generation ROS1/TRK/ALK tyrosine...
Hangzhou Minsheng Healthcare Aims to Raise RMB890 Million in Shenzhen GEM IPO
Hangzhou Minsheng Healthcare Co., Ltd. (SHE: 301507) is poised to raise RMB890 million through an...
RemeGen’s Telitacicept Shows Positive Phase III Results in Rheumatoid Arthritis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced positive results from the China...
Shanxi Jinbo Bio-pharmaceutical Plans Fundraise with Private Placement and IPO Proceeds
China-based Shanxi Jinbo Bio-pharmaceutical Co., Ltd. (832982.BSE) is poised to raise RMB 36.75 million through...
CCDI Cartoon Exposes “Prescription Data Rebates” Corruption in China’s Healthcare System
China’s Central Commission for Discipline Inspection (CCDI), the country’s anti-graft bureau, has released a cartoon...
Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data
Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing...
Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance
The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...
Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies
Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics....